BRIEF-Arch Biopartners' AB569 receives positive opinion from EMA COMP

Tue Apr 26, 2016 8:50am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

April 26 (Reuters) - Arch Biopartners Inc

* Arch biopartners' AB569 receives positive opinion from EMA COMP for orphan designation for cystic fibrosis

* Plans to submit an investigational new drug application to FDA for AB569 in second half of 2016

* COMP's positive opinion will be forwarded to EC for final approval of orphan designation, expected to be completed in next few weeks Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)